Wine "reduces Barret's Esophagus risk 56%"

16 March 2009

Drinking one glass of wine a day may lower the risk of Barrett's Esophagus by 56%, according to a new study by scientists at Kaiser  Permanente, the USA's largest non-profit health insurer. The condition  is a precursor to esophageal cancer, the country's fastest-growing  cancer with an incidence rate that has jumped 500% in the last 30  years.

This is the first and largest population-based study to examine the  connection between alcohol consumption and risk of Barrett's Esophagus.  Funded in part by the US National Institutes of Health, the Kaiser  Permanente study looked at 953 men and women in Northern California  between 2002 and 2005 and found that those who drank one or more  glasses of red or white wine a day had less than half the risk of the  condition. However, there was no reduction of risk among people who  drank beer or liquor.

Barrett's Esophagus affects 5% of the population and occurs when  heartburn or acid reflux permanently damages the esophageal lining.  Sufferers have a 30- to 40-fold higher risk of developing esophageal  adenocarcinoma. Because there are no symptoms or warning signs of  Barrett's Esophagus, people discover they have it when an endoscopy  for anemia, heartburn or a ulcer reveals the condition.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight